J2 Capital Management Inc Makes New $639,000 Investment in Cencora, Inc. (NYSE:COR)

J2 Capital Management Inc purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,842 shares of the company's stock, valued at approximately $639,000.

A number of other institutional investors also recently modified their holdings of COR. Ieq Capital LLC lifted its position in shares of Cencora by 8.7% during the second quarter. Ieq Capital LLC now owns 9,613 shares of the company's stock worth $2,166,000 after acquiring an additional 768 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Cencora by 26.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,809 shares of the company's stock worth $1,759,000 after purchasing an additional 1,626 shares in the last quarter. Bridges Investment Management Inc. bought a new position in Cencora in the 2nd quarter worth about $318,000. AE Wealth Management LLC grew its holdings in Cencora by 2.5% during the 2nd quarter. AE Wealth Management LLC now owns 18,826 shares of the company's stock valued at $4,242,000 after buying an additional 468 shares in the last quarter. Finally, Sei Investments Co. increased its position in shares of Cencora by 2.5% during the second quarter. Sei Investments Co. now owns 275,154 shares of the company's stock valued at $61,994,000 after buying an additional 6,626 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company's stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock valued at $22,862,734 over the last three months. Insiders own 15.80% of the company's stock.

Cencora Price Performance

NYSE:COR traded up $1.22 during mid-day trading on Friday, reaching $242.11. The stock had a trading volume of 1,492,998 shares, compared to its average volume of 993,012. The stock has a market capitalization of $46.80 billion, a P/E ratio of 32.24, a P/E/G ratio of 1.48 and a beta of 0.49. The firm has a 50 day moving average price of $237.52 and a two-hundred day moving average price of $234.01. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a one year low of $214.77 and a one year high of $253.27.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date was Friday, November 15th. This is a boost from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is presently 29.29%.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Robert W. Baird lifted their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Leerink Partners decreased their target price on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Finally, Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $275.60.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.